Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti
- Address
- Viale Europa 22, 32100 Belluno, Italy
Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti
The Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti is a comprehensive healthcare institution engaged in diverse clinical research across multiple therapeutic areas. The center demonstrates particular expertise in oncology research, with a strong focus on breast cancer prevention and treatment, as well as advanced studies in prostate cancer, lung cancer, colorectal cancer, and hematologic malignancies.
- Breast cancer research, including prevention strategies using low-dose tamoxifen and lifestyle interventions in high-risk women, and management of hormone therapy-related vasomotor symptoms
- Advanced radiation oncology studies investigating stereotactic body radiation therapy (SBRT) protocols for prostate cancer treatment optimization
- Cardiovascular disease research, particularly peripheral arterial disease management using anti-inflammatory approaches
- Immunotherapy trials in advanced non-small-cell lung cancer and follicular lymphoma, combining targeted therapies with immune checkpoint inhibitors
The center's research portfolio also extends to infectious disease prevention, including vaccine studies for respiratory syncytial virus in older adults. With involvement in both early-phase and phase III randomized controlled trials, the institution contributes to advancing evidence-based treatment strategies across precision medicine and personalized therapeutic approaches. Their comprehensive approach encompasses prevention, treatment optimization, and quality of life management for patients across multiple disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase IIb Randomized Study of Adjuvant Durvalumab and Regorafenib Versus Control in Stage IV Colorectal Cancer Patients with No Evidence of Disease | IRCCS Ospedale Policlinico San Martino | Phase II | Not Recruiting | Oct 2021 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bendamustine | 1 | Unknown | 2021-12-01 | 2021-12-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.